DOCSLIB.ORG

WO 2010/017504 Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2010/017504 Al (12) INTERNATIONALAPPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 11 February 2010 (11.02.2010) WO 2010/017504 Al (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, C07C 269/04 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US2009/053 196 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 7 August 2009 (07.08.2009) NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (25) Filing Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/087,056 7 August 2008 (07.08.2008) US GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, 61/086,821 7 August 2008 (07.08.2008) US ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, (71) Applicants (for all designated States except US): XENO- ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, PORT, INC. [US/US]; 3410 Central Expressway, Santa MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, Clara, CA 9505 1 (US). GLAXO GROUP LIMITED TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, ML, MR, NE, SN, TD, TG). Greenford, Middlesex UB6 ONN (GB). Declarations under Rule 4.17: (72) Inventors; and — as to the identity of the inventor (Rule 4.17 (ϊ)) (75) Inventors/Applicants (for US only): RAILLARD, Stephen, P. [US/US]; 964 Trophy Drive, Mountain — as to applicant's entitlement to apply for and be granted View, CA 94040 (US). MANTHATI, Suresh, K. a patent (Rule 4.1 7(H)) [IN/US]; 175 Calvert Drive, Apt. D102, Cupertino, CA — as to the applicant's entitlement to claim the priority of 95014 (US). LIU, Peng [CN/US]; 709 Swedeland Road, the earlier application (Rule 4.1 7(Hi)) King Of Prussia, PA 19406 (US). DAI, Qunying [CN/US]; 709 Swedeland Road, King Of Prussia, PA Published: 19406 (US). YIN, Hao [CN/US]; 709 Swedeland Road, — with international search report (Art. 21(3)) King Of Prussia, PA 19406 (US). — before the expiration of the time limit for amending the (74) Agents: WALKER, David et al; 370 Seventeenth Street, claims and to be republished in the event of receipt of Suite 4700, Denver, CO 80202 (US). amendments (Rule 48.2(h)) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (54) Title: METHODS OF SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS (57) Abstract: The present disclosure relates to methods of synthesizing l-(acyloxy)-alkyl carbamate prodrugs and to intermedi- ates used in the methods. Formula I METHODS FOR SYNTHESIZING 1-(ACYLOXY)-ALKYL CARBAMATE PRODRUGS [001] This application claims priority to U.S. Provisional Application Serial Nos. 61/087,056 filed August 7, 2008, and 61/086,821 filed August 7, 2008, each of which is incorporated by reference in its entirety. Field [002] Methods of synthesizing l-(acyloxy)-alkyl carbamate prodrugs of amine- containing drugs such as gabapentin, pregabalin, baclofen, and tranexamic acid, and intermediates used in the methods are disclosed. Background [003] The oral bioavailability of certain drugs can be improved by conversion to prodrugs. Certain prodrugs are derivatives of the parent drug in which a functional group is "masked" by a promoiety. Following administration to a patient the prodrug is metabolized to release the parent drug. [004] The 1-(acyloxy)-alkyl functionality is an example of a promoiety that has been used to functionalize amino containing drugs such as gabapentin, pregabalin, baclofen, and tranexamic acid. Gabapentin ([l-(aminomethyl)cyclohexyl]acetic acid) is an FDA approved drug that is marketed for the treatment of post herpetic neuralgia and epilepsy. l-{[( -Isobutanoyloxyethoxy)carbonyl]aminomethyl}-l-cyclohexane acetic acid is a 1- (acyloxy)-alkyl carbamate prodrug of gabapentin that has utility in the treatment of epilepsy (Gallop et al, WO 02100347), pain (Gallop et al, WO 02100347), particularly neuropathic pain or pain associated with irritable bowel syndrome, anxiety (Gallop et al, WO 02100347), particularly general anxiety disorder, alcohol dependency or ethanol withdrawal syndrome (Gallop et al, WO 02100347), restless legs syndrome (Barrett and Canafax, WO 2005027850), migraine prophylaxis (Barrett and Cundy, US 20080161393), fibromyalgia (Barrett and Cundy, US 20080161393), and hot flashes (Barrett and Gallop, WO 2004089289), particularly hot flashes associated with menopause. Pregabalin ((S)-3- (aminomethyi)-5-methyl-hexanoic acid) is an FDA approved drug that is marketed for the treatment of post herpetic neuralgia, fibromyalgia, and epilepsy. Pregabalin is not absorbed from the lower gastrointestinal tract and exhibits a short half life in vivo, and therefore frequent dosing is required to maintain therapeutic levels in the body. (3S)-{[l-Isobutanoyloxyethoxy]carbonylaminomethyl}-5-methyl-hexanoic acid, (3S)- {[1-isobutanoyloxyisobutoxy] carbonylaminomethyl} -5-methyl-hexanoic acid, and (3S)-{[l-benzoyloxyethoxy]carbonylaminomethyl}-5-methyl-hexanoic acid are examples of l-(acyloxy)-alkyl carbamate prodrugs of the GABA analog pregabalin, (3S)-aminomethyl-5- methyl-hexanoic acid, which exhibit high bioavailability as pregabalin when dosed either orally or directly into the colon of a mammal (Gallop et ah, US 6,972,341 and US 7,186,855; and Yao et al, U.S. Application Nos. 12/358,454 and 12/358,507 filed January 23, 2009). [005] The l-(acyloxy)-alkyl promoiety has also been used to provide prodrugs of R- baclofen ((R)-4-amino-3-(4-chlorophenyl)butanoic acid). Gallop et al, US 7,109,239 and US 7,300,956 disclose 1-(acyloxy)-alkyl carbamate prodrugs of R-baclofen such as (3R)-4- {[(lS)-2-methyl-l-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4- chlorophenyl)butanoic acid. R-Baclofen is known to be useful for treating spasticity and gastro-esophageal reflux disease (van Herwaarden et ah, Aliment. Pharmacol. Ther. 2002, 16(9), 1655-62; Ciccaglione and Marzio, Gut 2003, 52(4), 464-70; Andrews et ah, US 6,1 17,908; and Fara et ah, WO 02096404); in promoting alcohol abstinence in alcoholics (Gessa et ah, WO 0126638); in promoting smoking cessation (Gessa et ah, WO 0108675); in reducing addiction liability of narcotic agents (Robson et ah, US 4,126,684); in the treatment of emesis (Bountra et ah, US 5,719,185); as an anti-tussive for the treatment of cough (Kreutner et ah, US 5,006,560); as well as for treating neuropathic and musculoskeletal pain (Benson et ah, US 200901 18365), movement disorders such as dystonia and hiccups; peripheral nerve disorders such as muscle stimulation disorders; spinal cord disorders such as spastic paraparesis; cranial nerve disorders such as glossopharyngeal neuralgia and trigeminal neuralgia; multiple sclerosis; and cerebral palsy. [006] The l-(acyloxy)-alkyl promoiety has also been used to provide prodrugs of tranexamic acid ( rarø-4-(aminomethyl)-cyclohexanecarboxylic acid). For example, Zerangue et ah, US 7,351,740, disclose l-(acyloxy)-alkyl carbamate prodrugs of tranexamic acid such as 4-({[(2- methylpropanoyloxy)ethoxy]carbonylamino}methyl)cyclohexanecarboxylic acid, which is a l-(acyloxy)-alkyl carbamate prodrug of tranexamic acid. Tranexamic acid is known to be useful in treating bleeding such as excessive menstrual bleeding (menorrhagia), bleeding associated with cardiac surgery, upper gastrointestinal hemorrhage, blood loss in patients with advanced cancer, bleeding that occurs during dental procedures in hemophiliacs, and skin conditions such as wound healing, epidermal hyperplasia, skin roughening, unwanted skin pigmentation, and tumor metastasis (Zerangue et ah, US 7,351,740). [007] Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs are disclosed in Gallop et ah, US 6,818,787, US 6,927,036, US 6,972,341, US 7,186,855, and US 7,227,028; Raillard et ai, US 7,232,924; Gallop and Bhat, WO 200501001 1; and in Alexander, US 4,760,057, US 4,916,230, and US 5,684,018. [008] Other methods of synthesizing 1-(acyloxy)alkyl carbamate prodrugs are more recently disclosed by Raillard et at., U.S. Provisional Application No. 61/087,038 filed August 7, 2008. Summary [009] Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs are disclosed. [0 10] In a first aspect, methods of synthesizing a compound of Formula (I) or a salt thereof are disclosed comprising: reacting a compound of Formula (V) or a salt thereof with a primary or secondary amine-containing drug HNR9R10 to provide a compound of Formula (Ia): (I) and, when R 1 1 is a leaving group in the compound of Formula (Ia), the method comprises reacting the compound of Formula (Ia) or a salt thereof with a carboxylic acid of formula R1- COOH in the presence of an organic base, or with a salt of a carboxylic acid of formula R1- COOH to provide the compound of Formula (I) or a salt thereof; wherein: 1 R is chosen from C1-6 alkyl, substituted C1-6 alkyl, C3-6 cycloalkyl, substituted C3-6 cycloalkyl, phenyl, substituted phenyl, and C7- phenylalkyl; R 1 1 is chosen from a leaving group and -OC(O)-R 1; 2 3 R and R are independently
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • New Antiarrhythmic Agents for Atrial Fibrillation
    REVIEW New antiarrhythmic agents for atrial fibrillation Anirban Choudhury2 Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical and Gregory YH Lip†1 practice, with an incidence that increases twofold every decade after 55 years of age. †Author for correspondence Despite recent advances in our understanding of the mechanisms of AF, effective treatment †1University Department of Medicine, City Hospital, remains difficult in many patients. Pharmacotherapy remains the mainstay of treatment and Birmingham, B18 7QH, UK includes ventricular rate control as well as restoration and maintenance of sinus rhythm. In Tel.: +44 121 5075080 the light of studies demonstrating safety concerns with class IC agents, class III agents such Fax: +44 121 554 4083 [email protected] as sotalol and amiodarone have become the preferred and most commonly used drugs. 2University Department Unfortunately, a plethora of side effects often limits the long-term use of amiodarone. of Medicine, City Hospital, Thus, there have been many recent developments in antiarrhythmic drug therapy for AF Birmingham, B18 7QH, UK that have gained more interest, particularly with the recent debate over rate versus rhythm Tel.: +44 121 5075080 Fax: +44 121 554 4083 control. It is hoped that the availability of the newer agents will at least provide a greater choice of therapies and improve our management of this common arrhythmia. Atrial fibrillation (AF) is the most common many existing ones have significant side effects arrhythmia encountered in clinical practice [1]. It and limitations of efficacy. affects 5% of the population above the age of 65 years and 10% above 75 years [2].
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Self-Measured Compared to Office
    Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Supplemental Tables and Figures Part 1: Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension Table 1.1 Electronic search terms used for the current meta-analysis (Part 1 – Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension). PubMed Search (Blood Pressure Monitoring, Ambulatory [mesh] OR self care [mesh] OR telemedicine [mesh] OR patient participation [tiab] OR ambulatory [tiab] OR kiosk [tiab] OR kiosks [tiab] OR self-monitor* [tiab] OR self-measure* [tiab] OR self-care* [tiab] OR self-report* [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR home monitor* [tiab] OR telehealth [tiab] OR tele-health [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR telemedicine [tiab] OR patient-directed [tiab] OR Blood pressure monitoring “patient directed” [tiab] OR HMBP [tiab] OR SMBP [tiab] OR home [tiab] OR white coat [tiab] OR concept + Self Care concept ((patient participation [ot] OR ambulatory [ot] OR kiosk [ot] OR kiosks [ot] OR self-monitor* [ot] OR self-measure* [ot] OR self-care* [ot] OR self-report* [ot] OR telemonitor* [ot] OR tele-monitor* [ot] OR home monitor* [ot] OR telehealth [ot] OR tele-health [ot] OR telemonitor* [ot] OR tele- monitor* [ot] OR telemedicine [ot] OR patient-directed [tiab] OR “patient directed” [tiab]
    [Show full text]
  • Multimedia Appendix 1. Search Strategy Developed for Medline Via Ovid to Identify Existing Systematics Review. Concept 1: BP
    Multimedia Appendix 1. Search strategy developed for Medline via Ovid to identify existing systematics review. Concept 1: BP lowering regimens 1 exp antihypertensive agents/ 2 (antihypertensive$ adj (agent$ or drug)).tw. 3 exp thiazides/ 4 (chlorothiazide or benzothiadiazine or bendroflumethiazide or cyclopenthiazide or metolazone or xipamide or hydrochlorothiazide or hydroflumethiazide or methyclothiazide or polythiazide or trichlormethiazide or thiazide?).tw. 5 (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or oxodolin or thalitone or hygroton or indapamide or metindamide).tw. 6 ((loop or ceiling) adj diuretic?).tw. 7 (bumetanide or furosemide or torasemide).tw. 8 exp sodium potassium chloride symporter inhibitors/ 9 (eplerenone or amiloride or spironolactone or triamterene).tw. 10 or/1-9 11 exp angiotensin-converting enzyme inhibitors/ 12 ((angiotensin$ or kininase ii or dipeptidyl$) adj3 (convert$ or enzyme or inhibit$ or recept$)).tw. 13 (ace adj3 inhibit$).tw. 14 acei.tw. 15 exp enalapril/ 16 (alacepril or altiopril or benazepril or captopril or ceronapril or cilazapril or delapril or enalapril or fosinopril or idapril or imidapril or lisinopril or moexipril or moveltipril or pentopril or perindopril or quinapril or ramipril or spirapril or temocapril or trandolapril or zofenopril or teprotide).tw. 17 or/11-16 18 exp Angiotensin II Type 1 Receptor Blockers/ 19 (angiotensin$ adj4 receptor$ adj3 (antagon$ or block$)).tw. 20 exp losartan/ 21 (KT3-671 or candesartan or eprosartan or irbesartan or losartan or
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]